Bayer, PCB and Toxic Chemicals

Bayer Says It Was Told by Jury to Pay $100 Million Over Toxic Chemicals
Bayer AG was told by a jury to pay $100 million to four people at a Seattle-area school who said their exposure at the facility to toxic chemicals made by the company’s Monsanto unit caused brain damage and other injuries.
Bayer must pay $100 million in latest trial over PCBs in Washington school, jury finds
A Washington state jury on Tuesday said Bayer must pay $100 million to four people who say they were sickened by exposure to toxic chemicals known as PCBs made by the company's predecessor Monsanto that were used in light fixtures at a Seattle-area school,
Bayer Hit With $100 Million Verdict Over School’s Toxic PCBs (2)
Bayer AG was told by a jury to pay $100 million to four people at a Seattle-area school who said their exposure at the facility to toxic chemicals made by the company’s Monsanto unit caused brain damage and other injuries.
Bayer Hit with $100 Million Verdict in Toxic Chemical Lawsuit
A Washington jury has ordered Bayer to pay $100 million to four plaintiffs sickened by PCBs at a Seattle-area school. However, the company was not held liable for claims by 11 others. Bayer, which acquired Monsanto in 2018,
Jury orders Bayer to pay $100 million over PCBs in Washington school
By Brendan Pierson and Dietrich Knauth (Reuters) -A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals known as PCBs at a Seattle-area school,

Bayer Leverkusen edge Mainz 1-0

Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
Cutting Middle Management: Bayer's Costly Experiment One Year Later
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
Bayer sees new drugs boosting return to growth in 2027, WSJ reports
Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...
Bayer plant doch keine Pharma-Großdeals, Fokus Schuldenabbau
Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...
The Western Producer5h
Bayer introduces FieldView Drive 2.0 at Crop Production Show 2025
Bayer used the Western Canadian Crop Production Show in Saskatoon this week to introduce Prairie farmers to its new FieldView ...
Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
Bayer to Scale Back Health Dealmaking Amid Push to Pay Down Debt
Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...
pharmaphorum22h
Bayer makes progress with two-pronged Parkinson's attack
Bemdaneprocel is administered by surgical transplantation into a part of the brain known as the putamen, in the hope of ...